DLDragana Lavrnic

Dragana Lavrnic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dragana Lavrnic has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Survival and mortality of adult‐onset myasthenia gravis in the population of Belgrade, Serbia

    by Ivana Basta, Tatjana PekmezoviĆ, Stojan Peric, Ana NikoliĆ, Vidosava RakoČeviĆ‐StojanoviĆ, Zorica SteviĆ, Dragana LavrniĆ

    Introduction: The objective of this study was to estimate mortality and survival in a large cohort of myasthenia gravis (MG) patients from Belgrade, Serbia, during the period 1979–2008. Methods: Data for all patients with MG were collected from hospital records and the Belgrade MG Registry. Results: Within the 30‐year study period, death occurred in 107 (20%) of 562 patients with MG, with MG‐related fatality below 2%. The average MG mortality rate was 1.76 per 1,000,000 population (1.26/1,000,000 women, 2.45/1,000,000 men). A statistically significant increase was recorded for the average standardized mortality rate for all patients (P < 0.01). The mean survival from disease onset was 34.3 ± 2.0 years. Significantly shorter survival was observed in men compared with women and in patients older than 50 years compared with younger ones (P < 0.01). Discussion: We observed long survival and low frequency of MG‐related fatalities but increasing average standardized mortality rate, most notably in older men with MG. Muscle Nerve 58: 708–712, 2018


  • Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia)

    by Ivana Z. Basta, Tatjana D. Pekmezović, Stojan Z. Perić, Darija B. Kisić-Tepavčević, Vidosava M. Rakočević-Stojanović, Zorica D. Stević, Dragana V. Lavrnić

    The aim of this study was to assess factors that might influence the health-related quality of life (HRQoL) in patients with myasthenia gravis (MG). A cross-sectional study was performed including 230 consecutive patients with MG. Severity of the disease was estimated according to the MGFA classification and QMG score. HRQoL was assessed by the SF-36 questionnaire. Depressive and anxiety symptoms were assessed using the Hamilton rating scales for depression and anxiety, respectively. Social support was measured by the Multidimensional Scale of Perceived Social Support (MSPSS), and acceptance of the disease by the Acceptance of Illness Scale. The significant demographic predictors of worse HRQoL in MG patients were older age (p = 0.025) and lower education (p = 0.012). Among clinical features, significant independent contributing factors of worse HRQoL were more severe form of the disease according to MGFA (p = 0.001) and higher QMG score (p = 0.001). Finally, psychosocial predictors of worse quality of life were lower MSPSS score (p = 0.001), poor acceptance of the disease (p = 0.001), as well as higher levels of anxiety and depression (p = 0.001). Our study revealed that the HRQoL in patients with MG is similarly reduced in its psychological and physical aspects. These results may have a practical implication pointing out that different aspects of psychosocial support should be added to the regular therapeutic protocols.


  • Proton magnetic resonance spectroscopy of the intrinsic tongue muscles in patients with myasthenia gravis with different autoantibodies

    by Dragana Lavrnic, Marko Dakovic, Stojan Peric, Vidosava Rakocevic-Stojanovic, Ivana Basta, Ivan Marjanovic, Tatjana Stosic-Opincal, Slobodan Lavrnic


  • Open Access

    Serbian Validation of the Individualized Neuromuscular Quality of Life Questionnaire (INQoL) in Adults With Myotonic Dystrophy Type 1

    by Peric, Stojan Peric, Valeria Sansone, Dragana Lavrnic, Giovanni Meola, Ivana Basta, Marina Miljkovic, Vidosava Rakocevic-Stojanovic


    • 24 July 2007
      • Vol. 135, 216-21

    [Myasthenia gravis--a disease with variable impact on working capability].

    by Slobodan Apostolski, Dragana Lavrnić, Rajko Trikić, Vidosava Stojanović, Zorica Stević, Sanja Pavlović, Ivana Basta, Ana Nikolić

    Myasthenia gravis (MG) is a heterogeneous disease composed of several entities with disturbed neuromuscular transmission. The most frequent and clinically most important form of MG is an acquired autoimmune MG which includes more than 90% of all patients with failure of neuromuscular transmission. The main clinical feature of MG is changeable pathologic fatigability and weakness of one or more skeletal muscles and variable distribution of affected muscles. The disease is characterized by relapses and remissions. In 15% of patients the symptoms are limited to extraocular muscles causing variable ptosis, squint and double vision (Ocular MG). In remaining 85% of patients, during the first three years, the disease involves the majority of the head, neck and extremity skeletal muscles (Generalized MG). The clinical diagnosis may be sufficiently established by typical history, present or induced neurological signs of changeable muscle weakness and positive pharmacological tests. The assessment of the severity of the disease as well as the assessment of working capability is performed according to the classification recommended by Myasthenia Gravis Foundation of America (MGFA). The standardized score of the disease severity is based on testing function and strength of 9 groups of skeletal muscles. At the onset of the disease, regardless of the clinical form, the patient is incapable of work and subjected to hospitalization, clinical investigation and treatment. The efficacy of anticholinesterase drugs, thymectomy and/or immunosuppression determines the working capability and is recommended to be assessed six months after the initiation of treatment procedure.

    • 27 January 2007
      • Vol. 134, 453-6

    [Epidemiology of myasthenia gravis].

    by Tatjana Pekmezović, Dragana Lavrnić, Mirjana Jarebinski, Slobodan Apostolski

    Myasthenia gravis (MG) is an organ-specific autoimmune disorder characterized by weakness and fatigue of voluntary muscles, and presence of autoantibodies to acetylcholine receptor of postsynaptic muscle membrane. A review of the international literature suggests that there is large variety of MG frequency and distribution. An annual incidence rate of MG is thought to be between 0.25 and 20 per 1,000,000 population. The prevalence of MG in world shows even wider variation, i.e. ranging from 50/1,000,000 in Hong Kong to 200/1,000,000 in Virginia (USA). Among population of Belgrade, an average annual incidence rate during the period 1983-1992 was 7.1/1,000,000, and prevalence on December 31, 1992 was 121.5/1,000,000. The mortality rate of MG is very low with value under 1/1,000,000. Epidemiological studies of MG have indicated trend of increasing MG prevalence with relatively stable incidence. This reflects the impact of effective treatment, improved diagnostic methods and prolonged survival. Due to development of intensive care facilities and immunomodulating treatment, the mortality of MG has significantly decreased. The most common age of MG onset is between 20 and 40 years. In this age group, about 60% of patients are women, while sex ratio at older age is 1:1. Stressful life events, viral infections, pregnancy and delivery may precipitate the development of MG. MG is associated with other autoimmune diseases in about 30% of cases. Although the number of patients with MG continues to rise, it is still a rare disease. Further epidemiological research with a view to establish population registries and to estimate economic impact of disease on population as well as quality of life of patients with MG is needed.